Clinical Trial Update: Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) [Phase 2]

View source ↗

Summary

This update reports completion of a Phase 2 trial of darolutamide in patients with androgen receptor–positive salivary gland carcinoma (DISCOVARY).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer

Drugs mentioned

• Nubeqa (darolutamide)

Snippet

Sponsor: National Cancer Center Hospital East | Conditions: Salivary Gland Cancer | Phase 2 | Status: COMPLETED